InTheseTimes.com

 

Spin Doctors

While we greatly respect Barbara Seaman's other work, she is wrong in her assessment of Norplant ("Under My Skin," January 8). Her article is factually inaccurate, and her attacks on the Population Council are unfair and unwarranted. The Population Council has long been an advocate of voluntary choice of contraception, of balanced and complete information to patients and providers, of ethical conduct of clinical trials, and of women's reproductive health and rights.

Seaman should investigate the role of lawyers and journalists in the "demise" of a safe, effective, long-acting contraceptive. With a drumbeat of negative media over several years, it is no wonder that many women think using the implant "would be bad for them." Although many women have been involved in Norplant-related lawsuits in the United States, not one class action lawsuit was ever certified, and not one plaintiff has ever won her case.

Seaman contends that women were not told of possible side effects. This was one of the issues addressed in the lawsuits in the United States: In all cases, the court found that the distributor had adequately informed physicians about the method; it is the physician's responsibility to inform the patient.

In listing numerous possible side effects, Seaman also failed to note that these are side effects common to all hormonal methods, including the birth control pill. Without question, those women who have troubling bleeding problems should choose to have their implants removed, and the removals should be performed by competent and trained providers. Those women who find Norplant use acceptable should be able to obtain it and have removal on demand. Indeed, satisfied Norplant users around the world are now using their second set of implants.

Much is known about Norplant. At least 120 articles about efficacy, side effects and acceptability have been published. Seaman's allegations about the risk of ectopic pregnancy and the numbers of women who have had difficult removals are exaggerations; the article also ignores evidence about the safety of Norplant to infants of mothers who began breastfeeding six weeks after childbirth.

The article confuses clinical trials, over which sponsors have great control, with use following regulatory approval, over which sponsors have little control. It blames the contraceptive method instead of judges and legislators who ordered the implants used coercively in the United States. It condemns the FDA for not requiring patient informed consent forms until recently, although Norplant has had such an informed consent since 1995.

The Population Council encourages the use of modern contraception by women and men in the exercise of free choice to regulate their own fertility. Adoption of contraception should always be a voluntary, informed choice, with the individual making the decision whether to use contraception, which method to use, when to use it, and when to stop or try another. While Norplant is not for all women, we at the Population Council believe in expanding all women's contraceptive options, not restricting them.

Suellen Miller and Sandra Waldman
The Population Council
New York

 

Barbara Seaman replies: I stand by everything I said. I urge the Population Council to reconsider its policy of blaming outside elements ("the feminists" ... "the media" ... "the lawyers" ... "the judges and legislators") when women turn away from flawed birth control technologies. Full disclosure is the only way to go. Women expect it now. And please ask Population Council scientist and Norplant developer Sheldon Segal and his cronies to stop belittling the women's health movement. It's almost 30 years since Segal attacked me in his Family Planning Perspectives cover story "Is Contraception a Male Chauvinist Plot?"

It's hard to take you seriously as a scientific organization when you persist in putting your own defensive "spin" on your mistakes. For example, a blue-ribbon study by the Columbia University School of Public Health ("Determinants of Early Implant Discontinuation Among Low-Income Women," Family Planning Perspectives, November/December 1996) states:

Our findings indicate that the impact of exposure to negative media coverage was relatively modest. ... Another key finding is that negative experiences associated with the implant clearly play a role in a woman's decision to discontinue method use. ... The most frequently cited main reasons for removal of the implant were menstrual side effects (28%) and headaches (19%), findings consistent with previous research. Approximately 10% of respondents cited arm discomfort or infection and another 9% cited weight changes (primarily weight gain) as their main reason for early removal. Seven percent attributed discontinuation to mood changes, while 5% mentioned either hair loss, chest pains or negative media reports as their main reason for removal.

Regarding factual inaccuracies, it's you, not me, who perpetuate them, sometimes recklessly. For example, we know that hormone residues are found in the breast milk of Norplant users, but we have no idea what the long-range effects on the adult reproductive system of the nursing infant might turn out to be. It's too soon to tell. What's more, nursing mothers are unlikely to conceive, so why stick them with a hormonal contraceptive? History may well look back on this as a naive, ill-advised and shameful experiment, echoing the use of diethylstilbestrol (DES) in pregnant women during the postwar era, whose children's reproductive abnormalities--including cancer--were not uncovered for 25 years.

You say that I "blame the contraceptive method instead of judges and legislators who ordered the implants used coercively in the United States." To the contrary, my article acknowledges that: "In the United States, some judges, prison officials and state legislators have tried to mandate Norplant for women convicted of child abuse, as well as for poor women receiving welfare."

Fortunately, nearly all such attempts have been rebuffed or overturned by cooler heads in our democratic society. The area where Norplant users do perceive coercion is at the family planning clinic level. Out of 687 low-income Norplant users interviewed in New York, Texas and Pittsburgh over a two-year period, 40 percent anticipated or experienced that "cost barriers" could get in the way of having Norplant removed. The authors of that study, led by Drs. Debra Kalmuss and Andrew Davidson at the Center for Population and Family Health at Columbia University, urge that "family planning clinics need to make clear that they follow a policy of Norplant removal on demand, regardless of the patient's ability to pay."

In support of his beliefs, Davidson helps administer the Norplant Foundation Supply and Removal Program, which receives a couple of thousand phone calls a month. Most want removals.

 

 

Bottom Navigation Home Archives Contact Us About In These Times Subscribe to In These Times